VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies Limited Expands global Reach with the Launch of Elores in Ecuador.12-10-2023
12-10-2023
VENUS REMEDIES LTD. - 526953 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance under Reg 74(5) of SEBI of DP regulations.09-10-2023
VENUS REMEDIES LTD. - 526953 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Stop Transfer under regulation 39(3) of SEBI LODR, 2015.26-09-2023
VENUS REMEDIES LTD. - 526953 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Stop Transfer intimation under Regulation 39(3) of SEBI LODR(2015)23-09-2023
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies Limited honored with best working conditions award 2022.21-09-2023
Venus Remedies gets Serbian approval for oncology drugs, shares rise
Venus Remedies has secured five marketing approvals exclusively in the oncology space within the Serbian market20-09-2023
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies extends its oncology portfolio in South Eastern Europe with Serbian marketing approval for gemcitabine and docetaxel.20-09-2023
Venus Remedies gains on registering with govt body; to get custom duty exemption
"This exemption will not only enable us to reduce production costs but also empower us to invest more in research and development, enhancing our competitiveness and expanding our global reach," said Saransh Chaudhary, chief of research at Venus Remedies.14-09-2023
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies Limited attains the DSIR registration for customs duty exemption.13-09-2023